ZHONGXIANG TANG^1,2, LILI WANG^1,2, GUOJUN WU^1,2, LING QIN^1,2,*, YURONG TAN^1,2,*

BIOCELL, Vol.47, No.11, pp. 2503-2516, 2023, DOI:10.32604/biocell.2023.031565

Abstract Background: Non-small cell lung cancer (NSCLC) has a poor prognosis with a low 5-year survival rate. Lung adenocarcinoma (LUAD) accounts for 50%. Facio-genital dysplasia-5 (FGD5), a member of a subfamily of Rho GTP-GDP exchange factors, may be a good molecular biomarker for diagnosis and prognosis. Objective: To explore the clinical application of FGD5, the study was designed to investigate the prognosis value of FGD5 expression and its correlation with immune infiltrates in LUAD patients. Methods: Through the Wilcoxon signed-rank test and logistic regression, the correlation between clinical characteristics and FGD5 expression was analyzed. Kaplan–Meier plotter analysis, Cox regression, and a… More > Graphic Abstract

HENG LI^1,#, YOUMING LEI^3,#, GAOFENG LI¹, YUNCHAO HUANG^2,*

Oncology Research, Vol.32, No.1, pp. 187-197, 2024, DOI:10.32604/or.2023.030656

Abstract Lung cancer is a prevalent malignancy, and fatalities of the disease exceed 400,000 cases worldwide. Lung squamous cell carcinoma (LUSC) has been recognized as the most common pathological form of lung cancer. The comprehensive understanding of molecular features related to LUSC progression has great significance in LUSC prognosis assessment and clinical management. In this study, we aim to identify a panel of signature genes closely associated with LUSC, which can provide novel insights into the progression of LUSC. Gene expression profiles were retrieved from public resources including gene expression omnibus (GEO) and the cancer genome atlas (TCGA) database. Differentially expressed… More >

LU LIU^1,2, BIN XIE^1,2, WEI ZHU^1,2, QIUYAN HE^1,2, JIANHUA ZHOU^1,2, SHUANG LIU³, YONGGUANG TAO⁴, DESHENG XIAO^1,2,*

Oncology Research, Vol.31, No.3, pp. 275-286, 2023, DOI:10.32604/or.2023.028227

Abstract Background: Lung cancer is one of the most lethal cancers worldwide, but studies have shown that the higher the expression of programmed cell death protein 1 ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC), the more likely it will benefit from anti-PD-L1 immunotherapy. The purpose of our study was to collect and analyze abundant clinical samples in order to provide evidence for clinicians and patients who might consider anti-PD-L1 immunotherapy while jointly formulating treatment plans. Methods: On the one hand, we obtained cases from The Cancer Genome Atlas (TCGA) database, including 498 lung squamous cell cancer (LUSC) patients and… More >